Covered recipient · General Payments record
SUSAN T CURTIS
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$426.89
- Reported across 25 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $304.17 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $114.40 | 7 |
| Abbott Laboratories | $88.28 | 4 |
| Astellas Pharma US Inc | $21.93 | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $17.34 | 1 |
| ABIOMED | $16.90 | 1 |
| Amgen Inc. | $16.14 | 1 |
| Lilly USA, LLC | $15.17 | 1 |
| ABBVIE INC. | $14.01 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.27 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125292693 | CMS |
| Abbott Laboratories | $23.16 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125292695 | CMS |
| Abbott Laboratories | $19.24 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125292697 | CMS |
| Abbott Laboratories | $21.61 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125292699 | CMS |
| ABBVIE INC. | $14.01 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106976581 | CMS |
| ABIOMED | $16.90 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142269643 | CMS |
| Amgen Inc. | $16.14 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117232003 | CMS |
| Astellas Pharma US Inc | $21.93 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139534608 | CMS |
| Lilly USA, LLC | $15.17 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135916691 | CMS |
| Novo Nordisk Inc | $16.64 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100648911 | CMS |
| Novo Nordisk Inc | $13.23 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100396206 | CMS |
| Novo Nordisk Inc | $16.49 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100456446 | CMS |
| Novo Nordisk Inc | $15.20 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100494063 | CMS |
| Novo Nordisk Inc | $14.76 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100646365 | CMS |
| Novo Nordisk Inc | $15.95 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100234876 | CMS |
| Novo Nordisk Inc | $22.13 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100648205 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $17.34 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118841359 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.